FDA’s new focus on drug affordability could reshape approval speed—key insight for investors eyeing pharma innovation and market access
The FDA’s New Voucher Program: A Game-Changer for Drug Affordability and Innovation? The Food and Drug Administration (FDA) recently unveiled a bold shift in its drug approval strategy that could reshape the pharmaceutical landscape—and investors … Read more